Harnessing the epigenome to boost immunotherapy response in non-small cell lung cancer patients
The introduction of immune checkpoint inhibitor (ICI)-based therapy for non-oncogene addicted non-small cell lung cancer (NSCLC) has significantly transformed the treatment landscape of the disease. Inhibitors of the programmed cell death protein 1/programmed death-ligand 1 (PD-1/PD-L1) immune check...
Gardado en:
| Principais autores: | , , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
SAGE Publishing
2021-05-01
|
| Series: | Therapeutic Advances in Medical Oncology |
| Acceso en liña: | https://doi.org/10.1177/17588359211006947 |
| Tags: |
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|